Dr. McKay Discusses Immunotherapy Trials in RCC

Rana R. McKay, MD
Published: Monday, Dec 11, 2017



Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma (RCC).

Data presented at the 2017 ESMO Congress showed that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival and response rates for patients with intermediate- and poor-risk disease, says McKay.

Currently, there are phase III trials exploring combinations of VEGF and immunotherapy in RCC, such as the combination of cabozantinib (Cabometyx) plus nivolumab with or without ipilimumab, and the combination of axitinib (Inlyta) and pembrolizumab (Keytruda).
 


Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy trials in renal cell carcinoma (RCC).

Data presented at the 2017 ESMO Congress showed that the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival and response rates for patients with intermediate- and poor-risk disease, says McKay.

Currently, there are phase III trials exploring combinations of VEGF and immunotherapy in RCC, such as the combination of cabozantinib (Cabometyx) plus nivolumab with or without ipilimumab, and the combination of axitinib (Inlyta) and pembrolizumab (Keytruda).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x